BRNS · Barinthus Biotherapeutics plc.
$0.57
-0.03 (-5.16%)
At close · Jul 28
Market Cap
$23.28M
Shares
40.85M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| William Enright | CEO | $2,362,959 |
| Gemma Brown | CFO | $1,106,925 |
| Graham Griffiths | COO | $896,035 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| William Enright | CEO | $1,811,611 |
| Graham Griffiths | COO | $731,060 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| William Enright | CEO | $2,085,399 |
| Meg Marshall | Chief Medical Officer | $922,055 |
| Graham Griffiths | Chief Operating Officer | $753,971 |
| Thomas G. Evans | Chief Scientific Officer | $752,537 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Meg Marshall | Chief Medical Officer | $3,177,632 |
| William Enright | CEO | $2,739,095 |
| Georgy Egorov | Chief Financial Officer | $2,303,773 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| William Enright | Chief Executive Officer and Director | $3,368,628 |
| Georgy Egorov | Chief Financial Officer | $1,116,865 |
| Meg Marshall | Chief Medical Officer | $684,162 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Douglas Swirsky | Chief Financial Officer and principal accounting officer | Appointed | 2026-04-22 |
| Douglas Swirsky | Chief Financial Officer and principal accounting officer | Appointed | 2026-04-22 |
| Gemma Jones | principal accounting officer | Resigned | 2026-03-31 |